Developing novel biological drugs for complex chronic diseases
Targeting TGF-β for fibrosis and cancer.
RADBIO is a biotech company founded in 2018 by experienced scientists and entrepreneurs, designing and developing a novel biomolecule that neutralizes TGF-β, as a therapeutic for fibrotic diseases and solid tumors with unmet medical needs.
TGF-β is a well validated target known as the “master regulator of fibrosis”. We aim at harnessing the potential application of our biomolecule in several indications where TGF-β isoforms are upregulated.
DISCOVERY & CHARACTERIZATION
PROOF OF CONCEPT STUDIES
PRECLINICAL CMC / GLP-TOX
Inhibitor of TGF-β signaling pathway